The drug sector in India presents a intricate landscape, increasingly marked by concerns surrounding monopoly . While the nation boasts a vibrant generic sector , a few major companies hold a substantial share of the sales, prompting questions about competition and patient access to inexpensive treatments. This situation is fueled by a combination

The medicinal landscape in the nation is increasingly characterized by a pattern toward market consolidation, with a handful of prominent companies wielding significant power. These business giants, often bolstered by long-standing distribution networks and strong brand recognition, present a complex picture for competition and affordable healthcar

The Indian pharmaceutical industry, known for its affordable and accessible medicines, faces rising concerns about monopolies. A few dominant players control a significant portion of the market, potentially hampering competition and driving up prices for consumers. This situation raises questions about the long-term impact on patient access to aff